FindTrial
Sign In

The sencond allogeneic hematopoietic stem cell transplant for the treatment of leukemia relapse after donor lymphocyte infusion

The sencond allogeneic hematopoietic stem cell transplant for the treatment of leukemia relapse after donor lymphocyte infusion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002908
Enrollment
Unknown
Registered
2012-12-27
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leukemia

Interventions

1:second allo-HSCT

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. refractoty/relapsed leukemia patients undergoing first allo-HSCT relapsed after prophylactic DLI; 2. leukemia patients undergoing first allo-HSCT in CR relapsed after DLI for positive MRD.

Exclusion criteria

Exclusion criteria: 1. uncontrolled severe infection; 2. organ failure; 3. death within 30 days after relapse following first allo-HSCT.

Design outcomes

Primary

MeasureTime frame
disease free survival rate;—

Countries

China

Contacts

Public ContactXiao-Jun Huang
huangxiaojun@bjmu.edu.cn+86 10 88326006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026